麦冬皂苷D T6S1255

Product Introduction
Bioactivity


英文名: Ophiopogonin-D

描述: Ophiopogonin-D 通过 RIPK1 显着抑制前列腺细胞的体外和体内生长，OPD 可能被开发为潜在的抗前列腺癌药物。

细胞实验: The CCK-8 assay was used to assess the viability of prostate cancer cells.?The cell morphology was examined by an ultrastructural analysis via transmission electron microscopy.?Cells in apoptosis (early and late stages) were detected using an Annexin V-FITC/propidium iodide kit with a FACSCaliber flow cytometer.?JC-1, a cationic lipophilic probe, was employed to measure the mitochondrial membrane potential (MMP) of PC3 cells.?Changes in the protein expression of RIPK1, C-RIPK1, caspase 8, cleaved-caspase 8, Bim, Bid, caspase 10, and cleaved-caspase 10 were evaluated by Western blotting.?The mRNA expression of Bim was examined by quantitative real-time reverse transcription polymerase chain reaction.?Z-VAD-FMK (a caspase inhibitor) and necrostatin-1 (a specific inhibitor of RIPK1) were utilized to determine whether the cell death was mediated by RIPK1 or caspases[1].

动物实验: One week after tumor cell inoculation, mice bearing palpable tumors were randomly divided into control and treatment groups (8 mice/group).?OPD′ was dissolved in the vehicle, PEG400:Saline:Ethanol (400:300:200, v/v/v), and administered (via i.p. injection) at doses of 2.5 or 5.0 mg/kg bodyweight 5 days a week for 24 days.?The control group received vehicle only.?The mice were sacrificed by cervical dislocation on Day 24, and the tumor tissues were removed and weighed[1].

体外活性: Ophiopogonin D(OPD) was shown to exert potent anti-tumor activity against PC3 cells.?It induced apoptosis via a RIPK1-related pathway, increased the protein expression levels of RIPK1 and Bim, and decreased the levels of cleaved-RIPK1, caspase 8, cleaved-caspase 8, Bid, caspase 10, and cleaved-caspase 10.?OPD' also increased the mRNA expression of Bim.?The protein expression of Bim was decreased when cells were pre-treated with necrostatin-1[1].

体内活性: Ophiopogonin D(OPD)′ treatment led to significant tumor growth inhibition at a dose of 5.0 mg/kg bodyweight, beginning on Day 6 of treatment (p = 0.034).?At the end of the study (Day 24), the tumor tissues were excised, photographed, and weighed.?Treatment with 5.0 mg/kg bodyweight OPD′ resulted in significant (p = 0.000) tumor growth inhibition by approximately 79.8% on Day 24 compared to the vehicle treatment.?The 5.0 mg/kg dose led to significantly stronger tumor growth inhibition than the 2.5 mg/kg dose (p = 0.000).?There was not a significant loss of body weight in any of the groups[1].

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 30 mg/mL (35.09 mM)


关键字: Ophiopogonin D | Ophiopogonin-D | OphiopogoninD

相关产品: 1,5,6-Trihydroxy-3-methoxyxanthone | Cyclocurcumin | Dalbergioidin | (E/Z)-GSK5182 | Clovamide | De-O-methyllasiodiplodin | Dehydroglyasperin D | Britannilactone diacetate | S1R agonist 2 | Protosappanin A

相关库: Antioxidant Compound Library | Pyroptosis Compound Library | Inhibitor Library | Anti-Obesity Compound Library | Anti-Cancer Active Compound Library | Traditional Chinese Medicine Monomer Library | Anti-COVID-19 Traditional Chinese Medicine Compound Library | Traditional Mongolian Medicine Compound Library | Natural Product Library | Bioactive Compound Library

麦冬皂苷D T6S1255信息由TargetMol中国为您提供，如您想了解更多关于麦冬皂苷D T6S1255报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途